Welcome!

News Feed Item

Global Hemoglobin A1c Monitoring Industry

NEW YORK, April 14, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Hemoglobin A1c Monitoring Industry
http://www.reportlinker.com/p0197150/Global-Hemoglobin-A1c-Monitoring-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as -

Abbott Laboratories
ARKRAY, Inc.
Axis-Shield plc
Bayer Healthcare Diabetes Care
Beckman Coulter, Inc.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definition and Scope of Study I-3
HbA1c Laboratory Testing I-3
HbA1c Point of Care Testing I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1
A Quick Primer II-1
Growth Stimulants in a Nutshell II-2
Major Concerns II-2
Increasing Diabetes Prevalence - A Major Growth Propeller II-3
Table 1: Worldwide Prevalence of Diabetes Mellitus by Region
(2013 & 2035) (includes corresponding Graph/Chart) II-4

Table 2: Incidence of Diabetes in Select Countries (2013 &
2035) (includes corresponding Graph/Chart) II-4

Table 3: World's Health Expenditure on Diabetes by Region
(2013E): Spending (in US$ Billion) by People Diagnosed with
Diabetes in the Age Group 20-79 Years to Treat Diabetes and
Manage Associated Complications (includes corresponding
Graph/Chart) II-5

Table 4: Global Expenditure on Diabetes Treatment (2012):
Spending (in US$ Billion) by Income Strata (includes
corresponding Graph/Chart) II-5
Rapidly Aging Demographics and Growing Incidence of Diabetes:
Major Driving Factors II-5
Table 5: Elderly Population (60+ Years) as a Percentage of
Total Population (2012 & 2050) (includes corresponding
Graph/Chart) II-6

Table 6: Global Aging Population (60+) and their Proportion
of Total Population (2012) (includes corresponding
Graph/Chart) II-7
Increasing Obesity Levels Underpins Market Growth II-8
Table 7: Global Obesity Population (2013) (includes
corresponding Graph/Chart) II-8

Table 8: Prevalence of Adult Obesity in Select Countries
(2012) (includes corresponding Graph/Chart) II-9
Developing Nations: Future Growth Opportunities II-9
Increase in Healthcare Spending in Emerging Markets II-10
Table 9: Healthcare Spending as % of GDP in Select Countries
(2011) (includes corresponding Graph/Chart) II-10
Manufacturers Focus on Offering Products for Developing Markets II-11
Near Patient Testing Gaining Ground II-11
Regular HbA1c Test Keeps Heart Risk at Bay II-11
Diabetes Diagnosis: Opportunities for HbA1c Testing II-11
Is HbA1c Test Right in Being Recommended for Diagnostic
Purposes? II-12
Glycosylated Hemoglobin Tests: Paving Way for Early Stage
Diabetes Diagnosis II-12
Technology Developments Revolutionize Diagnostics in Diabetes
Care II-13
POC Testing: Positive Opportunities in Store II-13

Complex Competitive Environment Prevails in POC Diagnostics
Market II-14
POC HbA1c Tests: Significant Advantages over Lab Tests II-14
Major Testing Methods in POC HbA1c Tests II-15
Immunoassays II-15
Boronate Affinity Chromatography II-15
Micro-Optical Detection Methods II-16
Select HbA1c POC Tests in the Market - A Comparison II-16
Home Monitoring: Laced with Accuracy Concerns II-17
Glycated Albumin - A Potential Threat to HbA1c? II-17
Higher Levels of Glycosylated Hemoglobin Increases Risk of Death II-18
Non-Invasive Glucose Meters and CBGM Devices Threatens HbA1c
Market II-18
ESC and ADA Release Revised Guidelines for HbA1c Testing II-19
Competitive Landscape II-20
Table 10: Leading Players in the Global HbA1c Reagent Market
(2012): Percentage Breakdown of Revenues for Bayer Diabetes
Care, Siemens, and Others (includes corresponding
Graph/Chart) II-20

2. DIABETES - A BRIEF PROFILE OF THE DISEASE II-21
What Causes Diabetes? II-21
Types of Diabetes II-21
Major Types of Diabetes II-22
Likely Complications II-22
Nephropathy (Kidney Disease) II-22
Diabetic Neuropathy (Nerve Damage) II-22
Retinopathy (Damage to the Eye and Blindness) II-23
Poor Healing of Infections and Wounds II-23
Impotence in Men II-23
Periodontal Disease II-23
Cardiovascular Disease II-23
Interpreting the A1c Range II-23
Blood Glucose Level Guidelines in the US II-24
A Glance at Key Diabetes Statistics II-24
Table 11: World Diabetes and Population Statistics (2013 &
2035) (includes corresponding Graph/Chart) II-24

Table 12: World Diabetes and Population Statistics (in
Million) by Region (2013E & 2035P) - Breakdown by Africa,
Middle East and North Africa, Europe, North America and
Caribbean Region, South and Central America, South East Asia,
and Western Pacific (includes corresponding Graph/Chart) II-25
Prevalence of Diabetes in Various Parts of the World II-26
Table 13: Global Prevalence of Diabetes Mellitus (in Million)
by Gender (2013E) - Breakdown by Region for Africa, Middle
East and North Africa, Europe, North America and Caribbean
Region, South and Central America, South East Asia, and
Western Pacific (includes corresponding Graph/Chart) II-26

Table 14: Global Prevalence of Diabetes Mellitus (in Million)
by Age Group (2013) - Breakdown by Region for Africa, Middle
East and North Africa, Europe, North America and Caribbean
Region, South and Central America, South East Asia, and
Western Pacific Region (includes corresponding Graph/Chart) II-27

Table 15: World Diabetes Market (2013 & 2035): Top 10 Regions
with Highest Number of People Diagnosed with Diabetes (in
Million) in Age Group 20-79 years (includes corresponding
Graph/Chart) II-28

Table 16: Proportion of Undiagnosed Diabetes Cases (20-79
Years) by Region (2013E) (includes corresponding Graph/Chart) II-29

Table 17: Proportion of Deaths on Account of Diabetes in
People Aged Less than 60 Years by Region (2013E) (includes
corresponding Graph/Chart) II-29
Therapeutic Options for Diabetes II-30
Oral Medications for Type 2 Diabetes II-30
Side Effects of Insulin Therapy II-31
Maintaining A1c Test Result Below 7% II-31
Common Diabetes Management Practices II-31

3. PRODUCT OVERVIEW II-32
Hemoglobin - A Brief II-32
Hemoglobin A1c- Description II-32
HbA1c Monitoring II-32
What is A1c? II-32
1. HbA1c Laboratory Testing II-33
2. HbA1c Point of Care Testing & Self-Monitoring II-33
Hemoglobin A1c (HbA1c) Test II-33
Interpreting HbA1c Test Readings II-34
Result of Hemoglobin A1c Test II-34
Clinical Use of A1c Testing II-34
Advantages of A1c Assessment & Interpretation II-35
Risks Associated with HbA1c Testing II-35
Methods of Measurement for Glycohemoglobin II-35
Why Opt for HbA1c Testing? II-36

The Diabetes Control & Complications Trial (DCCT) II-36
The Kumamoto and UK Prospective Studies II-36
Glycemia Tests Used in Monitoring Diabetes II-36
Urine Glucose Testing II-37
Glycated Protein Testing II-37
Table 18: Relation Between A1c Level and Mean Plasma
Glucose Levels II-37
HbA1c Test Types II-38
HbA1c Laboratory Testing II-38
Analytical Techniques Used for Quantifying HbA1c in Labs II-38
Standardization of HbA1c Results II-38
Table 19: CAP Accuracy Grading for HbA1c Measurements (
2007-2013) II-39

Select Laboratory-based HbA1c Testing Products/Analyzers II-39
HbA1c Point of Care Testing & Self-Monitoring II-42
Select Point of Care HbA1c Testing Products/ Analyzers II-43
Standardization of Glycated Hemoglobin Testing II-45
NGSP Standardization of HbA1c II-46
IFCC Standardization of HbA1c II-46
HbA1c Reporting II-46
A1c (%) and Corresponding eAG Number (in mg/dl or mmol/l) II-47

4. PRODUCT APPROVALS/INTRODUCTIONS II-48
Piramal Enterprises Unveils Instant QDx Range of Diagnostic
Devices II-48
Roche Launches Cobas B 101 System for Managing Metabolic Syndrome II-48
Convergys® Launches POC HbA1c Analyzer II-48
Sanofi Showcases MyStar Extra® Self-Monitoring Meter II-49
Roche Unveils New HbA1c Test for Diagnosis of Diabetes II-49
Erba Mannheim Unveils New Hb-Vario HPLC System II-50
EKF Launches Quo-Test POC HbA1c Analyzer II-50
Roche Receives FDA Approval for COBAS INTEGRA 800 Tina-quant
HbA1cDx Assay II-50
Beckman Coulter Gets FDA Clearance for Hemoglobin A1c Assay Tests II-51
Pointe Scientific Launches A1c Automated Assay for Beckman DXC
600 Analyser II-51

Dynacare Upgrades Hematology Software in Hemoglobin A1C Testing II-51
Tosoh Bioscience Introduces GX Glycohemoglobin Analyzer II-51
Siemens Secures CE Marking for DCA HbA1c Test Kit II-52
EKF Obtains CE Mark for Quo-Lab POC HbA1c Analyser II-52
Streck Launches A1c-Cellular Linearity Verification Material II-53
Abbott Obtains CE Marking for ARCHITECT HbA1c (IA) Fully
Automated Assay II-53
Tosoh Bioscience Develops ST AIA-PACK HbA1c Assay II-54
Trinity Obtains FDA Approval for Premier Hb9210 HbA1c Device II-54
Siemens Launches Fortified Version of DCA Vantage Analyzer II-55
Tosoh Launches New Assay on its AIA-600II and AIA-360 Analyzers II-55

5. RECENT INDUSTRY ACTIVITY II-56
Quest Diagnostics Sells HemoCue Business to Radiometer II-56
Techne Takes Over Bionostics II-56

Express Diagnostics Takes Over Eveia Medical II-57
BioHermes Enters into Agreement to Acquire HbA1c Technology
from Scripps Laboratories II-57
HemoCue America Inks 5-Year Agreement with ARC II-57
Bio-Rad Laboratories Inks Development Agreement with Inpeco II-58
Danaher Acquires Beckman Coulter II-58
Alere Purchases Additional Shares of Axis-Shield II-58
EKF Diagnostics Inaugurates New Manufacturing Plant in the UK II-59
MinuteClinic Signs Agreement with Axis-Shield II-59
Trinity Inks Distribution Agreement with Menarini for Premier
Hb9210 II-59

6. FOCUS ON SELECT PLAYERS II-60
Abbott Laboratories (US) II-60
ARKRAY, Inc. (Japan) II-60
Axis-Shield plc (UK) II-61
Bayer Healthcare Diabetes Care (US) II-62
Beckman Coulter, Inc. (US) II-62
Bio-Rad Laboratories Inc (US) II-63

Diazyme Laboratories Inc. (US) II-64
EKF Diagnostics Holdings Plc (UK) II-64
HEMOCUE® AB (Sweden) II-65
Infopia Co. Ltd. (South Korea) II-65
Menarini Diagnostics Ltd. (UK) II-65
Roche Diagnostics (Switzerland) II-66
Siemens Healthcare Diagnostics (Germany) II-66
Tosoh Bioscience, Inc (US) II-67
Trinity Biotech plc (Ireland) II-67

7. GLOBAL MARKET PERSPECTIVE II-68
Table 20: World Recent Past, Current & Future Analysis for
HbA1c Monitoring by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2012 through 2020 (includes
corresponding Graph/Chart) II-68

Table 21: World Historic Review for HbA1c Monitoring by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2011 (includes corresponding
Graph/Chart) II-69

Table 22: World 15-Year Perspective for HbA1c Monitoring by
Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) II-70

Table 23: World Recent Past, Current & Future Analysis for
Laboratory-based HbA1c Monitoring by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2012 through
2020 (includes corresponding Graph/Chart) II-71

Table 24: World Historic Review for Laboratory-based HbA1c
Monitoring by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2006 through 2011 (includes
corresponding Graph/Chart) II-72

Table 25: World 15-Year Perspective for Laboratory- based
HbA1c Monitoring by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 2006, 2014 & 2020 (includes corresponding Graph/Chart) II-73

Table 26: World Recent Past, Current & Future Analysis for

Point-of-Care (POC)-based HbA1c Monitoring by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2012 through 2020 (includes corresponding Graph/Chart) II-74

Table 27: World Historic Review for Point-of-Care (POC)-based
HbA1c Monitoring by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2011 (includes
corresponding Graph/Chart) II-75

Table 28: World 15-Year Perspective for Point-of-Care
(POC)-based HbA1c Monitoring by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 2006, 2014 & 2020 (includes
corresponding Graph/Chart) II-76


III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1
Outlook III-1
HbA1c - Increasingly Moving into Physician's Office III-1
HbA1c Testing for Diabetes Detection Gains Support III-1
ADA Recommends HbA1c Test for Diabetes Diagnosis III-1
ADA Recommends New Guidelines for HbA1c Testing for Certain
Patients III-2
Rising Inclination towards CLIA-Waived Tests III-2
Need for Further Stringency in Requirements Arises III-2
Healthcare Reform Legislation: Impact on Diabetes Diagnostics III-3
US Near Patient HbA1c Testing - A Highly Consolidated Market III-4
Table 29: Leading Players in the US Near Patient HbA1c
Testing Market (2013): Percentage Share Breakdown of
Revenues for Siemens, Axis-Shield, and Others (includes
corresponding Graph/Chart) III-4
Diabetes Statistics in North America and Caribbean Region III-5
Table 30: North American and Caribbean Regional Population
and Diabetes Prevalence Statistics (2013E) - Top Regions
with High Prevalence of Diabetes by Age Group and Gender
(includes corresponding Graph/Chart) III-5

Table 31: Diabetes and Population Statistics in North
America and Caribbean Region (2013 & 2035) (includes
corresponding Graph/Chart) III-6
Diabetes Statistics in the US - An Overview III-6
Age Factor III-7
Table 32: Number of Diabetics by Gender in the US (2013E)
(in '000s) (includes corresponding Graph/Chart) III-7

Table 33: Number of Diabetics in the US by Age Group
(2013E) (in '000s) (includes corresponding Graph/Chart) III-7
Prevalence by Race/Ethnicity III-8
Table 34: US Market for Diabetes (2012): Percentage
Breakdown of Prevalence by Race/Ethnicity - Non-Hispanic
Blacks and Non-Hispanic Whites (includes corresponding
Graph/Chart) III-8
Mean HbA1c Scores at National Level III-9
Economic Burden of Diabetes in the US III-9
Table 35: Direct Medical Expenditure on Diabetes
Management in the US (2012): Percentage Share Breakdown of
Costs Incurred by Component (includes corresponding
Graph/Chart) III-9

Table 36: Indirect Costs of Diabetes in the US (2012):
Percentage Share Breakdown by Component (includes
corresponding Graph/Chart) III-10
Product Approvals/Launches III-10
Strategic Corporate Developments III-13
Key Players III-15
B.Market Analytics III-19
Table 37: US Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-19

Table 38: US Historic Review for HbA1c Monitoring by Segment-
Laboratory Testing and Point of Care Testing Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2011(includes corresponding
Graph/Chart) III-20

Table 39: US 15-Year Perspective for HbA1c Monitoring by

Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-21

2. CANADA III-22
A.Market Analysis III-22
Outlook III-22
Diabetes Statistics in Canada III-22
Table 40: Adult Diabetes Population by Gender in Canada
(2013) (In '000s) (includes corresponding Graph/Chart) III-22

Table 41: Adult Diabetes Population by Age Group in Canada
(2013) (In '000s) (includes corresponding Graph/Chart) III-23
B.Market Analytics III-23
Table 42: Canadian Recent Past, Current & Future Analysis
for HbA1c Monitoring by Segment - Laboratory Testing and
Point of Care Testing Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2012 through
2020 (includes corresponding Graph/Chart) III-23

Table 43: Canadian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-24

Table 44: Canadian 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-25

3. JAPAN III-26
A.Market Analysis III-26
Outlook III-26
ARKRAY, Inc. - A Major Player III-26
B.Market Analytics III-27
Table 45: Japanese Recent Past, Current & Future Analysis
for HbA1c Monitoring by Segment - Laboratory Testing and
Point of Care Testing Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2012 through
2020 (includes corresponding Graph/Chart) III-27

Table 46: Japanese Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-28

Table 47: Japanese 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-29

4. EUROPE III-30
A.Market Analysis III-30
Outlook III-30
Positive Outlook for Diabetes Diagnostics Market in Europe III-30
Proven Efficacy and Benefits of POCT HbA1C Tests Spur Adoption III-31
Competitive Environment III-31
Table 48: Leading Players in the European Point-of-Care
HbA1c Tests Market (2011): Percentage Share Breakdown of
Revenues for Axis-Shield, Hemocue, Siemens Healthcare
Diagnostics, and Others (includes corresponding
Graph/Chart) III-32
A Glance at Key Diabetes Statistics in Europe III-32
Table 49: Diabetes and Population Statistics in Europe
(2013 & 2035) (includes corresponding Graph/Chart) III-32

Table 50: European Population and Diabetes Prevalence
Statistics (2013E) - Select Regions with High Prevalence of
Diabetes for Age Groups (20-39, 40-59, and 60-79) and
Gender (includes corresponding Graph/Chart) III-33
B.Market Analytics III-34
Table 51: European Recent Past, Current & Future Analysis
for HbA1c Monitoring by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2012 through 2020 (includes corresponding
Graph/Chart) III-34

Table 52: European Historic Review for HbA1c Monitoring by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Thousand for Years 2006
through 2011 (includes corresponding Graph/Chart) III-35

Table 53: European Recent Past, Current & Future Analysis
for HbA1c Monitoring by Segment - Laboratory Testing and
Point of Care Testing Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2012 through
2020 (includes corresponding Graph/Chart) III-36

Table 54: European Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-37

Table 55: European 15-Year Perspective for HbA1c Monitoring
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-38

Table 56: European 15-Year Perspective for HbA1c Monitoring
by Segment -Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-39

4a. FRANCE III-40
Market Analysis III-40
Table 57: French Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-40

Table 58: French Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-41

Table 59: French 15-Year Perspective for HbA1c Monitoring by
Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-42

4b. GERMANY III-43
A.Market Analysis III-43
Outlook III-43
Product Approvals/Introductions III-43
Siemens Healthcare Diagnostics - A Key Player III-44
B.Market Analytics III-45
Table 60: German Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-45

Table 61: German Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-46

Table 62: German 15-Year Perspective for HbA1c Monitoring by
Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-47

4c. ITALY III-48
Market Analysis III-48
Table 63: Italian Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-48

Table 64: Italian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-49

Table 65: Italian 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-50

4d. THE UNITED KINGDOM III-51
A.Market Analysis III-51
Outlook III-51
Diabetes Statistics & Management - An Insight III-51
Rising Obesity Cases - Increased Risk of Diabetes III-51
Type 1 Diabetes in Children III-52
Table 66: Number of Type 1 Diabetics Per 100,000 Children
in Select Countries (2011) (includes corresponding
Graph/Chart) III-52
NHS England Launches Action for Diabetes Plan III-52
Strategic Corporate Developments III-53
Key Players III-54
B.Market Analytics III-56
Table 67: UK Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-56

Table 68: UK Historic Review for HbA1c Monitoring by Segment
- Laboratory Testing and Point of Care Testing Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2011 (includes corresponding
Graph/Chart) III-57

Table 69: UK 15-Year Perspective for HbA1c Monitoring by
Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-58

4e. SPAIN III-59
A.Market Analysis III-59
Outlook III-59
Product Launch III-59
B.Market Analytics III-60
Table 70: Spanish Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-60

Table 71: Spanish Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-61

Table 72: Spanish 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-62

4f. RUSSIA III-63
Market Analysis III-63
Table 73: Russian Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-64

Table 74: Russian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-65

Table 75: Russian 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-66

4g. REST OF EUROPE III-67
A.Market Analysis III-67
Outlook III-67
Strategic Corporate Developments III-67
Key Players III-69
B.Market Analytics III-71
Table 76: Rest of Europe Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-71

Table 77: Rest of Europe Historic Review for HbA1c
Monitoring by Segment - Laboratory Testing and Point of Care
Testing Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2011
(includes corresponding Graph/Chart) III-72

Table 78: Rest of Europe 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-73

5. ASIA-PACIFIC III-74
A.Market Analysis III-74
Outlook III-74
Diabetes Statistics - An Overview III-74
Table 79: Diabetes and Population Statistics in Western
Pacific (2013 & 2035) (includes corresponding Graph/Chart) III-75

Table 80: Western Pacific Population and Diabetes
Prevalence Statistics (2013E) - Select Regions with High
Prevalence of Diabetes for Various Age Groups (20-39,
40-59, and 60-79) and Gender (includes corresponding
Graph/Chart) III-76

Table 81: Diabetes and Population Statistics in South East
Asia (2013 & 2035) (includes corresponding Graph/Chart) III-77

Table 82: South East Asian Population and Diabetes
Prevalence Statistics (2013 Estimates) - Select Regions
with High Prevalence of Diabetes for Various Age Groups
(20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-77
B.Market Analytics III-78
Table 83: Asia-Pacific Recent Past, Current & Future
Analysis for HbA1c Monitoring by Geographic Region - China,
India and Rest of Asia-Pacific Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-78

Table 84: Asia-Pacific Historic Review for HbA1c Monitoring
by Geographic Region - China, India and Rest of Asia-Pacific
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-79

Table 85: Asia-Pacific 15-Year Perspective for HbA1c
Monitoring by Geographic Region - Percentage Breakdown of
Dollar Sales for China, India and Rest of Asia-Pacific
Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-80

Table 86: Asia-Pacific Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-81

Table 87: Asia-Pacific Historic Review for HbA1c Monitoring
by Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-82

Table 88: Asia-Pacific 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-83

5a. CHINA III-84
A.Market Analysis III-84
Outlook III-84
Increasing Diabetes Incidence Spurs Growth in Diabetes
Diagnostics Market III-84
Strategic Corporate Development III-85
B.Market Analytics III-86
Table 89: Chinese Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-86

Table 90: Chinese Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-87

Table 91: Chinese 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-88

5b. INDIA III-89
A.Market Analysis III-89
Outlook III-89
HbA1c Testing on Growth Spree III-89
Growth Stimulants & Challenges in a Nut Shell III-89
Rising Diabetes Cases - Opportunities for HbA1c Monitoring
Market III-90
Product Launch III-90
B.Market Analytics III-91
Table 92: Indian Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-91

Table 93: Indian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-92

Table 94: Indian 15-Year Perspective for HbA1c Monitoring by
Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-93

5c. REST OF ASIA-PACIFIC III-94
A.Market Analysis III-94
Outlook III-94
Diabetes Statistics in Australia III-94
Table 95: Diabetes Population Breakdown by Age Group in
Australia (2011-12) (includes corresponding Graph/Chart) III-94
Infopia Co. Ltd. (South Korea) - A Major Player III-95
B.Market Analytics III-95
Table 96: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-95

Table 97: Rest of Asia-Pacific Historic Review for HbA1c
Monitoring by Segment - Laboratory Testing and Point of Care
Testing Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2011
(includes corresponding Graph/Chart) III-96

Table 98: Rest of Asia-Pacific 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-97

6. LATIN AMERICA III-98
A.Market Analysis III-98
Outlook III-98
Diabetes in Latin America - A Glance at Key Statistics III-98
Table 99: Diabetes and Population Statistics in Central and
South America (2013 & 2035) (includes corresponding
Graph/Chart) III-99

Table 100: Central and South American Population and
Diabetes Prevalence Statistics (2013 Estimates) - Select
Regions with High Prevalence of Diabetes for Various Age
Groups (20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-99
B.Market Analytics III-100
Table 101: Latin American Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-100

Table 102: Latin American Historic Review for HbA1c
Monitoring by Segment - Laboratory Testing and Point of Care
Testing Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2011
(includes corresponding Graph/Chart) III-101

Table 103: Latin American 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-102

7. REST OF WORLD III-103
A.Market Analysis III-103
Outlook III-103
Diabetes Statistics in Africa and the Middle East III-103
Table 104: African Diabetes and Population Statistics (2013 &
2035) (includes corresponding Graph/Chart) III-103

Table 105: African Population and Diabetes Prevalence
Statistics (2013) - Select Regions with High Prevalence of
Diabetes for Various Age Groups (20-39, 40-59, and 60-79)
and Gender (includes corresponding Graph/Chart) III-104

Table 106: Diabetes and Population Statistics in Middle
East and North Africa (2013 & 2035) (includes corresponding
Graph/Chart) III-105

Table 107: Middle East and North African Population and
Diabetes Prevalence Statistics (2013 Estimates) - Select
Regions with High Prevalence of Diabetes for Various Age
Groups (20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-106
B.Market Analytics III-107
Table 108: Rest of World Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-107

Table 109: Rest of World Historic Review for HbA1c
Monitoring by Segment - Laboratory Testing and Point of Care
Testing Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2011
(includes corresponding Graph/Chart) III-108

Table 110: Rest of World 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-109

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 27 (including Divisions/Subsidiaries - 35)

The United States (14)
Canada (1)
Japan (3)
Europe (14)
- Germany (3)
- The United Kingdom (5)
- Italy (1)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (3)

To order this report: Global Hemoglobin A1c Monitoring Industry
http://www.reportlinker.com/p0197150/Global-Hemoglobin-A1c-Monitoring-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, will discuss how from store operations...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, will discuss some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he’ll go over some of the best practices for structured team migrat...
SYS-CON Events announced today that Datera will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera offers a radically new approach to data management, where innovative software makes data infrastructure invisible, elastic and able to perform at the highest level. It eliminates hardware lock-in and gives IT organizations the choice to source x86 server nodes, with business model option...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they bu...
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp emp...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
As people view cloud as a preferred option to build IT systems, the size of the cloud-based system is getting bigger and more complex. As the system gets bigger, more people need to collaborate from design to management. As more people collaborate to create a bigger system, the need for a systematic approach to automate the process is required. Just as in software, cloud now needs DevOps. In this session, the audience can see how people can solve this issue with a visual model. Visual models ha...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...